BC Week In Review | Nov 30, 2018
Financial News

Pharmasset, Idenix vets lead HBV company Antios to $25M series A

Founded by former executives of HCV companies that scored big exits, Antios Therapeutics Inc. (Atlanta, Ga.) raised a $25 million series A round to develop a cure for HBV. Antios' co-founders include CEO Abel De...
BC Extra | Nov 27, 2018
Financial News

Pharmasset, Idenix vets lead HBV company Antios to $25M series A

Founded by former executives of HCV companies that scored big exits, Antios Therapeutics Inc. raised a $25 million series A round to develop a cure for HBV. Antios' co-founders include CEO Abel De La Rosa...
BC Week In Review | Oct 6, 2017
Clinical News

Merck discontinues HCV candidates MK-3682B and MK-3682C

Merck & Co. Inc. (NYSE:MRK) discontinued development of MK-3682B (grazoprevir/ruzasvir/uprifosbuvir) and MK-3682C (ruzasvir/uprifosbuvir), emptying its pipeline of candidates to treat HCV infection. The pharma based its decision on a review of Phase II efficacy data...
BC Week In Review | Oct 6, 2017
Clinical News

Merck discontinues HCV candidates MK-3682B and MK-3682C

Merck & Co. Inc. (NYSE:MRK) discontinued development of MK-3682B (grazoprevir/ruzasvir/uprifosbuvir) and MK-3682C (ruzasvir/uprifosbuvir), emptying its pipeline of candidates to treat HCV infection. The pharma based its decision on a review of Phase II efficacy data...
BC Extra | Sep 29, 2017
Clinical News

Merck discontinues HCV candidates

Merck & Co. Inc. (NYSE:MRK) discontinued development of MK-3682B (grazoprevir/ruzasvir/uprifosbuvir) and MK-3682C (ruzasvir/uprifosbuvir), emptying its pipeline of candidates to treat HCV infection. The pharma based its decision on a review of Phase II efficacy data...
BC Week In Review | Mar 3, 2017
Company News

Merck uprifosbuvir news

In an SEC filing, Merck said it would record a pretax impairment charge of $2.9 billion for HCV candidate uprifosbuvir ( MK-3862 ) based on "recent changes to the product profile, as well as changes to its...
BC Extra | Feb 24, 2017
Company News

Merck takes haircut on Idenix asset

A shifting HCV market and pricing pressure caused Merck & Co. Inc. (NYSE:MRK) to dramatically reduce its expectations for uprifosbuvir (MK-3862), which the pharma gained in its $3.9 billion acquisition of Idenix Pharmaceuticals Inc. in...
BC Week In Review | Dec 16, 2016
Company News

Gilead, Merck infectious news

A federal jury ordered Gilead to pay Merck $2.5 billion in damages in an HCV patent infringement lawsuit. According to the jury's verdict, the damages are based on a 10% royalty rate for Gilead's U.S....
BC Extra | Dec 16, 2016
Company News

Jury awards Merck $2.5B in Gilead patent dispute

A federal jury ordered Gilead Sciences Inc. (NASDAQ:GILD) to pay Merck & Co. Inc. (NYSE:MRK) $2.5 billion in damages in an HCV patent infringement lawsuit. According to the jury's verdict, the damages are based on...
BC Extra | Oct 21, 2015
Clinical News

Eight-week data for Merck's triple HCV combo

An abstract released ahead of next month's American Association for the Study of Liver Diseases (AASLD) meeting describes Phase II findings across multiple HCV genotypes produced by eight weeks of treatment with a once-daily regimen...
Items per page:
1 - 10 of 489
BC Week In Review | Nov 30, 2018
Financial News

Pharmasset, Idenix vets lead HBV company Antios to $25M series A

Founded by former executives of HCV companies that scored big exits, Antios Therapeutics Inc. (Atlanta, Ga.) raised a $25 million series A round to develop a cure for HBV. Antios' co-founders include CEO Abel De...
BC Extra | Nov 27, 2018
Financial News

Pharmasset, Idenix vets lead HBV company Antios to $25M series A

Founded by former executives of HCV companies that scored big exits, Antios Therapeutics Inc. raised a $25 million series A round to develop a cure for HBV. Antios' co-founders include CEO Abel De La Rosa...
BC Week In Review | Oct 6, 2017
Clinical News

Merck discontinues HCV candidates MK-3682B and MK-3682C

Merck & Co. Inc. (NYSE:MRK) discontinued development of MK-3682B (grazoprevir/ruzasvir/uprifosbuvir) and MK-3682C (ruzasvir/uprifosbuvir), emptying its pipeline of candidates to treat HCV infection. The pharma based its decision on a review of Phase II efficacy data...
BC Week In Review | Oct 6, 2017
Clinical News

Merck discontinues HCV candidates MK-3682B and MK-3682C

Merck & Co. Inc. (NYSE:MRK) discontinued development of MK-3682B (grazoprevir/ruzasvir/uprifosbuvir) and MK-3682C (ruzasvir/uprifosbuvir), emptying its pipeline of candidates to treat HCV infection. The pharma based its decision on a review of Phase II efficacy data...
BC Extra | Sep 29, 2017
Clinical News

Merck discontinues HCV candidates

Merck & Co. Inc. (NYSE:MRK) discontinued development of MK-3682B (grazoprevir/ruzasvir/uprifosbuvir) and MK-3682C (ruzasvir/uprifosbuvir), emptying its pipeline of candidates to treat HCV infection. The pharma based its decision on a review of Phase II efficacy data...
BC Week In Review | Mar 3, 2017
Company News

Merck uprifosbuvir news

In an SEC filing, Merck said it would record a pretax impairment charge of $2.9 billion for HCV candidate uprifosbuvir ( MK-3862 ) based on "recent changes to the product profile, as well as changes to its...
BC Extra | Feb 24, 2017
Company News

Merck takes haircut on Idenix asset

A shifting HCV market and pricing pressure caused Merck & Co. Inc. (NYSE:MRK) to dramatically reduce its expectations for uprifosbuvir (MK-3862), which the pharma gained in its $3.9 billion acquisition of Idenix Pharmaceuticals Inc. in...
BC Week In Review | Dec 16, 2016
Company News

Gilead, Merck infectious news

A federal jury ordered Gilead to pay Merck $2.5 billion in damages in an HCV patent infringement lawsuit. According to the jury's verdict, the damages are based on a 10% royalty rate for Gilead's U.S....
BC Extra | Dec 16, 2016
Company News

Jury awards Merck $2.5B in Gilead patent dispute

A federal jury ordered Gilead Sciences Inc. (NASDAQ:GILD) to pay Merck & Co. Inc. (NYSE:MRK) $2.5 billion in damages in an HCV patent infringement lawsuit. According to the jury's verdict, the damages are based on...
BC Extra | Oct 21, 2015
Clinical News

Eight-week data for Merck's triple HCV combo

An abstract released ahead of next month's American Association for the Study of Liver Diseases (AASLD) meeting describes Phase II findings across multiple HCV genotypes produced by eight weeks of treatment with a once-daily regimen...
Items per page:
1 - 10 of 489